|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ELN 6-K filed Aug 28, 2009. Research
and Development Expenses
Total R&D expenses were $171.6 million in the first
half of 2009, compared to $159.0 million in the same period
of 2008. Included within R&D expenses were other charges of
$10.2 million (2008: $3.1 million), as described
further in Note 5 to the interim financial statements.
Excluding other charges, R&D expenses increased 4% to
$161.4 million in the first half of 2009, compared to
$155.9 million in the first half of 2008. The increase was
primarily due to increased expenses associated with the
progression of our Alzheimer’s disease programmes.
This excerpt taken from the ELN 6-K filed Mar 30, 2009. Research
and Development Expenses
R&D expense increased 28% to $286.8 million in 2008
from $223.3 million in 2007. Included within R&D
expense were other charges of $7.5 million (2007:
$10.2 million), as described below. Excluding other
charges, R&D expense increased 31% to $279.3 million
in 2008, compared to $213.1 million in 2007. The increase
was primarily due to increased expenses associated with the
progression of our Alzheimer’s disease programmes,
including the advancement of bapineuzumab into Phase 3 clinical
trials and the advancement of ELND005 into Phase 2 clinical
trials. The increase in R&D expenses was partially offset
by our decision to reduce employee compensation and benefits
during 2008, compared to 2007 levels.
Table of Contents
This excerpt taken from the ELN 20-F filed Feb 26, 2009. Research
and Development Expenses
R&D expenses were largely flat over the three years at
$47.6 million in 2008, $48.4 million in 2007 and
$47.4 million in 2006.
This excerpt taken from the ELN 6-K filed Mar 31, 2008. Research
and Development Expenses
R&D expense increased 24% to $223.3 million in 2007
from $180.1 million in 2006. Included within R&D
expense was other charges of $10.2 million (2006:
$9.9 million), as described below. Excluding other charges,
R&D expense increased 25% to $213.1 million in 2007,
compared to $170.2 million in 2006. The increase was
primarily due to increased expenses associated with the
progression of our Alzheimer’s disease programmes and
particularly the advance of AAB-001 into Phase 3 clinical trials
and the advance of ELND005 into Phase 2 clinical trials during
2007. R&D expenses for 2007 included $39.3 million
(2006: $31.5 million) in relation to Tysabri.
This excerpt taken from the ELN 20-F filed Feb 28, 2008. Research
and Development Expenses
R&D expenses were $212.0 million in 2007,
$170.1 million in 2006 and $192.8 million in 2005. The
increase of 25% in 2007 compared to 2006 was primarily due to
increased expenses associated with the progression of our
Alzheimer’s disease programs and particularly the advance
of AAB-001 into Phase 3 clinical trials and the advance of
ELND005 into Phase 2 clinical trials during 2007. R&D
expenses for 2007 included $39.3 million (2006:
$31.5 million; 2005: $66.9 million) in relation to
Tysabri.
The reduction in total R&D expense of 12% in 2006 compared
to 2005 reflected the completion of the safety evaluation
related to Tysabri in 2005, partially offset by increased
spending relating to the progression of key Alzheimer’s
disease programs, particularly AAB-001, the initiation of new
collaborations in the areas of autoimmune diseases and
neurodegeneration with Archemix and Transition, respectively,
and by the cost of expensing share-based compensation of
$12.6 million in 2006 (2005: $Nil).
Table of Contents
This excerpt taken from the ELN 6-K filed Mar 30, 2007. Research
and Development Expenses
Total R&D expense was $224.6 million in 2006 and
$249.1 million in 2005, and included $31.5 million
(2005: $68.1 million) in relation to Tysabri. This
reduction of 10% reflects the completion of the safety
evaluation related to Tysabri in 2005, offset by
increased spending relating to the progression of key
Alzheimer’s programmes, particularly AAB-001, and the
initiation of new collaborations in the areas of autoimmune
diseases and neurodegeneration with Archemix and Transition.
This excerpt taken from the ELN 20-F filed Feb 28, 2007. Research
and Development Expenses
R&D expenses were $233.3 million in 2005, compared to
$257.3 million in 2004, and included $66.9 million
(2004: $84.2 million) in relation to Tysabri. The
decrease of 9% reflects cost containment initiatives, the
refocusing of R&D efforts on key Alzheimer’s disease
programs, and reduced spending on Tysabri as a result of
the completion of clinical trials, offset by the cost of the
extensive Tysabri safety evaluation.
This excerpt taken from the ELN 6-K filed Mar 31, 2006. Research and Development
Expenses
R&D expenses decreased by 5% to $249.1 million for 2005
from $262.6 million for 2004. R&D expenses include
exceptional operating expenses of $7.3 million in 2005
(2004: $Nil). Excluding exceptional items, R&D expenses
decreased from $262.6 million in 2004 to
$241.8 million in 2005 and included $66.9 million
(2004: $84.2 million) in relation to Tysabri. The
reduction reflects cost containment initiatives, the refocusing
of research and development efforts on key Alzheimer’s
programmes, and reduced spending on Tysabri as a result
of the completion of clinical trials, offset by the cost of the
extensive Tysabri safety evaluation.
This excerpt taken from the ELN 20-F filed Mar 30, 2006. Research
and Development Expenses
R&D expenses were $257.3 million in 2004 compared to
$277.6 million in 2003. The decrease of 7% reflects the
reduction in the scope of our R&D activities as a result of
the divestment of certain businesses and products, the
termination of certain R&D activities, and the refocusing of
our efforts on key programs: Tysabri, Prialt and
Alzheimer’s disease.
This excerpt taken from the ELN 6-K filed Apr 11, 2005. Research and Development Expenses R&D expenses, after exceptional items, decreased by 22% to $259.0 million for 2004 from $331.4 million for 2003. The decrease reflects the reduction in the scope of our R&D activities as a result of the divestment of certain businesses and products, the termination of certain R&D activities, and the refocusing of our efforts on key programmes: | EXCERPTS ON THIS PAGE:
|
| |||||||
